GLP-1 Receptor Agonists Monitoring Bundle: The Complete Prescriber Reference

What Is the GLP-1 Receptor Agonist Drug Class?

GLP-1 receptor agonists are peptide-based drugs that mimic endogenous glucagon-like peptide-1, an incretin hormone released from intestinal L-cells after meals. By binding GLP-1 receptors in the pancreas, brain, gut, and heart, they amplify glucose-dependent insulin release, suppress postprandial glucagon, slow gastric emptying, and signal satiety to the hypothalamus. The net clinical effect is lower blood glucose, reduced caloric intake, and, for several agents, reduced cardiovascular event rates independent of glucose control.

Class Members and Approved Indications

The FDA-approved GLP-1 RAs in current US practice are:

| Agent | Brand | Route | Frequency | Primary Indication | |---|---|---|---|---| | Semaglutide 0.5/1/2 mg | Ozempic | SC | Weekly | T2D, CV risk reduction | | Semaglutide 2.4 mg | Wegovy | SC | Weekly | Obesity | | Semaglutide 3/7/14 mg | Rybelsus | Oral | Daily | T2D | | Liraglutide 1.2/1.8 mg | Victoza | SC | Daily | T2D | | Liraglutide 3 mg | Saxenda | Oral | Daily | Obesity | | Dulaglutide 0.75 to 4.5 mg | Trulicity | SC | Weekly | T2D, CV risk reduction | | Exenatide ER 2 mg | Bydureon BCise | SC | Weekly | T2D | | Tirzepatide 2.5 to 15 mg | Mounjaro | SC | Weekly | T2D | | Tirzepatide 2.5 to 15 mg | Zepbound | SC | Weekly | Obesity |

Tirzepatide is a dual GIP/GLP-1 receptor agonist; it is included here because its clinical monitoring requirements, adverse-effect profile, and cardiovascular data closely parallel the pure GLP-1 RAs, and most prescribers manage it within the same protocols. FDA approval labeling for semaglutide and dulaglutide detail the full indication language.

Mechanism at the Receptor Level

Endogenous GLP-1 has a plasma half-life of 1 to 2 minutes because dipeptidyl peptidase-4 (DPP-4) degrades it rapidly. Pharmaceutical GLP-1 RAs are engineered with amino-acid substitutions, fatty-acid conjugates, or albumin binding to resist DPP-4 cleavage, extending half-lives to 2 hours (exenatide IR) through 7 days (semaglutide). Receptor occupancy drives cyclic AMP signaling in beta cells, which closes ATP-sensitive potassium channels and triggers calcium-mediated insulin granule exocytosis only when plasma glucose exceeds roughly 70 mg/dL. This glucose dependency is why monotherapy with a GLP-1 RA carries very low hypoglycemia risk [1].

Baseline Assessment Before the First Dose

Every patient starting a GLP-1 RA needs a structured pre-treatment workup. Skipping baseline labs removes the ability to detect drug-related changes and may expose patients to preventable harm.

Laboratory Panel

Order the following before the first injection or tablet:

• HbA1c (establishes glycemic baseline; guides dose targets)
• Fasting plasma glucose
• Comprehensive metabolic panel (CMP): serum creatinine, eGFR, electrolytes, liver enzymes
• Fasting lipid panel
• TSH (medullary thyroid carcinoma risk stratification)
• Urine albumin-to-creatinine ratio (UACR) (GLP-1 RAs may improve albuminuria; need baseline)
• Serum amylase and lipase (pancreatitis risk stratification; obtain if the patient has prior pancreatitis history or heavy alcohol use)
• Serum calcitonin is not universally mandated by guidelines but is reasonable if the patient has a neck mass or family history of thyroid cancer [2]

The American Diabetes Association (ADA) 2024 Standards of Care state: "Before initiating a GLP-1 receptor agonist, assess renal function and consider UACR to establish a cardiorenal baseline." [2]

Contraindication Screen

Ask specifically about:

1. Personal or family history of medullary thyroid carcinoma (MTC)
2. Multiple endocrine neoplasia type 2 (MEN2)
3. Prior pancreatitis (acute or chronic)
4. Gastroparesis or severe gastrointestinal motility disorders
5. Hypersensitivity to any GLP-1 RA excipient

Rodent studies showed thyroid C-cell tumors with liraglutide and semaglutide; human epidemiologic data have not confirmed increased MTC rates, but the class carries an FDA boxed warning [3]. Patients with a confirmed or suspected personal or family history of MTC must not receive any GLP-1 RA.

Pregnancy and Reproductive Considerations

GLP-1 RAs are rated FDA Pregnancy Category risk: avoid use. Animal studies showed embryofetal toxicity. Counsel women of childbearing potential to use contraception and discontinue the drug at least 2 months before a planned pregnancy given the prolonged tissue half-life of semaglutide [4].

Dose Titration Protocol

Titration schedules vary by agent, but all follow the same principle: start low, increase every 4 weeks, and hold at the highest tolerated dose rather than forcing the labeled maximum.

Semaglutide SC (Ozempic / Wegovy) Titration

For Ozempic (T2D indication):

• Weeks 1 to 4: 0.25 mg SC weekly (not a therapeutic dose; tolerance building only)
• Weeks 5 to 8: 0.5 mg SC weekly
• Week 9 onward: increase to 1 mg if additional glycemic control needed
• Week 13 onward: 2 mg available for further HbA1c reduction

For Wegovy (obesity indication), the titration extends over 16 weeks to the 2.4 mg maintenance dose [5].

Liraglutide (Victoza / Saxenda) Titration

• Week 1: 0.6 mg SC daily
• Week 2: 1.2 mg SC daily
• Week 3 (if tolerated): 1.8 mg SC daily for Victoza; continue weekly 0.6 mg increments to 3 mg for Saxenda

Patients who cannot tolerate the 1.8 mg dose after 4 weeks should be reassessed for alternative agents [6].

Tirzepatide (Mounjaro / Zepbound) Titration

• Start: 2.5 mg SC weekly for 4 weeks
• Increase by 2.5 mg every 4 weeks
• Target maintenance: 5 to 15 mg weekly based on response and tolerability

In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced mean weight loss of 20.9% at 72 weeks versus 3.1% with placebo (P<0.001) [7].

The Ongoing Monitoring Bundle

Once a patient is titrated to maintenance dose, monitoring shifts from weekly titration checks to a structured quarterly reassessment.

Every-Visit Checklist (At Each Clinic Contact During Titration)

• Weight and BMI
• Blood pressure and heart rate (GLP-1 RAs modestly increase resting heart rate by 2 to 4 bpm on average)
• Nausea, vomiting, diarrhea, constipation symptom query
• Review injection technique and site rotation
• Confirm no new contraindications (pregnancy, new pancreatitis symptoms)

Pulse elevation of more than 10 bpm above baseline should prompt reassessment of cardiovascular status and documentation [8].

Quarterly Labs at Maintenance

| Lab | Rationale | |---|---| | HbA1c | Primary glycemic endpoint | | Fasting glucose | Hypoglycemia risk if combined with sulfonylurea/insulin | | CMP (creatinine, eGFR) | Renal function; dose adjustment needed if eGFR <15 for exenatide | | UACR | Albuminuria trajectory | | Lipid panel | Semaglutide reduces LDL by ~5 to 8% and triglycerides by ~12% | | Weight | Obesity pharmacotherapy response assessment |

The LEADER trial (N=9,340) showed liraglutide 1.8 mg reduced the composite of cardiovascular death, nonfatal MI, and nonfatal stroke by 13% versus placebo (HR 0.87, 95% CI 0.78 to 0.97, P<0.001 for non-inferiority, P=0.01 for superiority) in patients with T2D and high cardiovascular risk [9].

Annual Extended Panel

• Thyroid palpation and TSH if not checked in 12 months
• Ophthalmology referral if diabetic retinopathy is present (semaglutide was associated with early worsening of retinopathy in SUSTAIN-6, likely due to rapid HbA1c reduction) [10]
• Bone density (DEXA) if the patient is losing more than 10% body weight, given that rapid weight loss may reduce bone mineral density [11]
• Depression/anxiety screening using PHQ-9; weight loss interventions carry mental health implications and FDA has required labeling updates for some obesity agents

Cardiovascular Outcome Data by Agent

This section matters for deciding which GLP-1 RA to prescribe in a patient with established cardiovascular disease or high 10-year ASCVD risk.

Semaglutide: SUSTAIN-6 and SELECT

SUSTAIN-6 (N=3,297) randomized patients with T2D to semaglutide 0.5 mg or 1 mg versus placebo. Over 104 weeks, the primary 3-point MACE endpoint occurred in 6.6% of semaglutide patients versus 8.9% of placebo patients (HR 0.74, 95% CI 0.58 to 0.95, P<0.001 for non-inferiority) [10].

SELECT (N=17,604) tested semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease but without diabetes. Over a mean follow-up of 39.8 months, semaglutide reduced MACE by 20% versus placebo (HR 0.80, 95% CI 0.72 to 0.90, P<0.001). This was the first CVOT to demonstrate cardiovascular benefit for a GLP-1 RA in a non-diabetic population [12].

Liraglutide: LEADER

As noted above, LEADER demonstrated HR 0.87 for 3-point MACE in 9,340 high-risk T2D patients. Cardiovascular death was specifically reduced (HR 0.78, 95% CI 0.66 to 0.93) [9].

Dulaglutide: REWIND

REWIND (N=9,901) is notable because 69% of enrolled patients had no prior cardiovascular event, making it the most primary-prevention-adjacent CVOT in the class. Dulaglutide 1.5 mg reduced MACE by 12% versus placebo (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) [13].

Exenatide ER: EXSCEL

EXSCEL (N=14,752) showed non-inferiority for MACE but did not reach superiority (HR 0.91, 95% CI 0.83 to 1.00, P=0.06 for superiority) [14].

HealthRX Cardiovascular Risk Stratification Framework for GLP-1 RA Selection:

• Established ASCVD or T2D + high CV risk: semaglutide or liraglutide (superiority data)
• Overweight/obesity without T2D + established CVD: semaglutide 2.4 mg (SELECT data)
• Primary prevention T2D with moderate CV risk: dulaglutide (REWIND population most representative)
• Glycemic priority without CV history: any agent; choose by tolerability and cost

Adverse Effects and Management

GLP-1 RAs share a class adverse-effect profile rooted in their gastrointestinal activity.

Gastrointestinal Effects

Nausea is the most common adverse effect, affecting 15 to 44% of patients depending on the agent and titration speed [15]. Vomiting occurs in 5 to 24%. Both are most pronounced during titration and typically resolve within 4 to 8 weeks at a stable dose.

Management strategies:

• Eat smaller portions; avoid high-fat meals during titration
• Take oral semaglutide (Rybelsus) 30 minutes before eating with no more than 4 oz of water (per label)
• Hold dose escalation if nausea scores are 7/10 or higher
• Consider a 4-week extended hold at the current dose before retrying escalation

Constipation affects 5 to 24% of patients and may persist at maintenance dose. Increase dietary fiber to 25 to 30 g/day and ensure adequate hydration (at least 2 L/day) before considering a laxative [16].

Pancreatitis

The FDA mandates a warning for acute pancreatitis across the class. Post-marketing pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) have identified pancreatitis signals, though a causal relationship remains debated [3]. A 2014 meta-analysis in JAMA Internal Medicine found no statistically significant increase in pancreatitis risk with GLP-1 RAs versus comparators [17].

Instruct patients to stop the drug and seek emergency care if they develop severe, persistent mid-epigastric pain radiating to the back. Do not restart after confirmed acute pancreatitis.

Thyroid C-Cell Risk

The FDA boxed warning stems from rodent carcinogenicity studies showing dose-dependent thyroid C-cell adenomas and carcinomas with liraglutide and semaglutide. Human observational data are reassuring but limited to 10 to 15 years of post-marketing follow-up [3]. A 2023 case-control study in JAMA Network Open (N=1.6 million patient-years) found a small but statistically significant association between GLP-1 RA use and thyroid cancer (adjusted OR 1.58 for papillary thyroid cancer specifically); the MTC signal was not statistically significant [18]. Educate all patients on thyroid symptoms: neck mass, dysphagia, dysphonia, dyspnea.

Injection Site Reactions

Subcutaneous nodules, erythema, or lipohypertrophy occur in roughly 3 to 5% of patients. Site rotation across abdomen, thigh, and upper arm reduces incidence. Rotate injection sites at least 1 cm from the previous site each week [5].

Drug Interactions

• Oral medications: Gastric emptying delay may reduce peak plasma concentration of orally administered drugs. Check timing of levothyroxine, oral contraceptives, and narrow-therapeutic-index drugs such as warfarin. Separate administration where possible.
• Insulin and sulfonylureas: Combining a GLP-1 RA with insulin or a sulfonylurea raises hypoglycemia risk. Reduce sulfonylurea dose by 50% at initiation in most patients; consider proactive insulin dose reduction of 10 to 20% [2].
• No clinically significant interaction with metformin or SGLT-2 inhibitors; these combinations are guideline-supported for T2D management [2].

Renal and Hepatic Dose Adjustments

Renal Impairment

• Semaglutide SC: No dose adjustment required for any level of renal impairment, including dialysis; semaglutide is metabolized proteolytically and not renally cleared [5].
• Liraglutide: No formal dose adjustment per label, but use caution in severe renal impairment; limited data available.
• Exenatide ER: Contraindicated if eGFR <30 mL/min/1.73m2; use caution between eGFR 30 to 50.
• Dulaglutide: No dose adjustment required through eGFR >15; avoid if eGFR <15 (data limited) [6].

Hepatic Impairment

No dose adjustment is required for any currently approved GLP-1 RA in mild to moderate hepatic impairment. Data in severe hepatic impairment (Child-Pugh C) are limited; use with caution and monitor closely for gastrointestinal adverse effects that may worsen hydration status [6].

Prescribing Considerations: Obesity Versus Type 2 Diabetes Indications

The distinction between obesity and T2D indications affects dosing, labeling, and insurer coverage.

Dosing Differences

Semaglutide 2.4 mg (Wegovy) uses a higher maintenance dose than Ozempic's 2 mg ceiling. The additional weight-loss benefit at 2.4 mg over 1 mg was approximately 3.4 additional percentage points of body weight in the STEP-1 trial (N=1,961), which showed 14.9% mean weight loss with 2.4 mg versus 2.4% with placebo at 68 weeks (P<0.001) [19].

Coverage and Step Therapy

Most commercial insurers require a BMI ≥30 or ≥27 with at least one weight-related comorbidity, documentation of a structured diet and exercise program for at least 6 months, and often a prior authorization form citing the specific obesity comorbidities. Medicare Part D covers Wegovy for cardiovascular risk reduction in patients meeting SELECT trial criteria (established CVD plus overweight/obesity) following the 2024 CMS expansion [20].

Discontinuation Rates and Weight Regain

Weight regain after stopping semaglutide is well documented. The STEP-4 withdrawal trial showed that patients who stopped semaglutide 2.4 mg at week 20 regained approximately two-thirds of their lost weight by week 120 [21]. This finding supports treating obesity as a chronic condition requiring ongoing pharmacotherapy, mirroring long-term statin use for dyslipidemia. Present this data to patients at initiation to set realistic long-term expectations.

Switching Between GLP-1 Receptor Agonists

Clinical scenarios that prompt a switch include inadequate glycemic or weight response, intolerable adverse effects, cost or formulary changes, and patient preference for weekly versus daily dosing.

Same-Class Switching Protocol

No washout period is required when switching from one GLP-1 RA to another. Start the new agent at its lowest titration dose regardless of the dose of the prior agent. The ADA 2024 Standards note that cross-tolerance to gastrointestinal adverse effects does not reliably transfer between agents [2]. A patient who tolerated liraglutide 1.8 mg well may still develop nausea when starting semaglutide 0.25 mg.

Document the reason for switching in the chart and repeat HbA1c at 12 weeks after reaching the new maintenance dose to assess comparative efficacy.